Table 2.
Distribution of initial and median sorafenib dose, dose modification, and reason for treatment discontinuation
| Variable | Before propensity score matching | After propensity score matching | ||||
|---|---|---|---|---|---|---|
| eGFR (mL/min/1.73 m2) | p-value | eGFR (mL/min/1.73 m2) | p-value | |||
| < 60 (N = 2531) | ≥ 60 (N = 2303) | < 60 (N = 1215) | ≥ 60 (N = 1215) | |||
| Starting sorafenib dose (mg), median (IQR) | 800.0 (0.0) | 800.0 (200.0) | 0.7524 | 800.0 (0.0) | 800.0 (0.0) | 0.3952 |
| Daily sorafenib dose, (mg/d), median (IQR) | 491.8 (415.9) | 529.3 (400.0) | < 0.0001 | 496.6 (415.8) | 525.3 (400.0) | 0.0028 |
| Relative sorafenib dose intensity (%), mean ± SD | 66.5 ± 27.1 | 69.7 ± 26.0 | < 0.0001 | 66.5 ± 27.1 | 69.7 ± 26.0 | 0.0034 |
| Duration of treatment (mo), median (IQR) | 5.22 (10.41) | 3.71 (8.77) | < 0.0001 | 4.30 (9.79) | 4.53 (9.66) | 0.2473 |
| Dose modification, n (%) | ||||||
| Reduction | 1338 (52.9) | 1001 (43.5) | < 0.0001 | 617 (50.8) | 562 (46.3) | 0.0256 |
| Interruption | 1048 (41.4) | 903 (39.2) | 0.1200 | 498 (41.0) | 511 (42.1) | 0.5925 |
| Discontinuation | 1875 (74.1) | 1907 (82.8) | < 0.0001 | 960 (79.0) | 972 (80.0) | 0.5465 |
| Reason for discontinuation, n (%) | ||||||
| Adverse events | 1045 (55.7) | 962 (50.5) | 0.0011 | 523 (54.5) | 511 (52.6) | 0.4007 |
| Insufficient effectiveness | 644 (34.4) | 757 (39.7) | 0.0007 | 347 (36.2) | 372 (38.3) | 0.3338 |
| Others | 281 (15.0) | 310 (16.3) | 0.2825 | 148 (15.4) | 134 (13.8) | 0.3101 |
IQR interquartile range